Proteomics

Dataset Information

134

Short Term Immune Response to IL6 inhibition (Tocilizumab)


ABSTRACT: we examined the effects of IL6 inhibition treatment on biologic molecular pathways in a 59 year old patient well diagnosed with RA with inadequate response to DMARD thus treated with tocilizumab. To assess the immunological outcome we used quantitative proteome analysis to evaluate changes in the proteome profile of different biologic pathways in leukocyte cell populations important to RA pathogenesis isolated by positive enrichment of CD14, CD4, CD8, CD19, and CD56.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Primary Cell, Leukocyte

DISEASE(S): Rheumatoid Arthritis

SUBMITTER: Allan Stensballe  

LAB HEAD: Allan Stensballe

PROVIDER: PXD002686 | Pride | 2016-01-05

REPOSITORIES: Pride

Similar Datasets

2022-07-04 | E-MTAB-9602 | biostudies-arrayexpress
2012-03-01 | E-MTAB-945 | biostudies-arrayexpress
2014-03-26 | E-MTAB-2232 | biostudies-arrayexpress
2010-11-10 | E-GEOD-25256 | biostudies-arrayexpress
2020-02-04 | E-MTAB-8285 | biostudies-arrayexpress
2017-03-29 | MSV000080787 | MassIVE
2021-01-08 | E-MTAB-9304 | biostudies-arrayexpress
2021-09-08 | PXD010723 | Pride
2022-03-24 | E-MTAB-11585 | biostudies-arrayexpress
2009-09-22 | E-GEOD-18175 | biostudies-arrayexpress